All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Fixed-duration acalabrutinib-venetoclax with or without obinutuzumab in CLL: Interim analysis of the AMPLIFY trial
Bookmark this article
|
Acalabrutinib is a highly selective BTKi with improved safety and tolerability vs ibrutinib.1 During the 66th ASH Annual Meeting and Exposition, Jennifer Brown presented the interim analysis of the phase III AMPLIFY trial (NCT03836261) evaluating the efficacy and safety of fixed duration acalabrutinib-venetoclax with/without obinutuzumab vs chemotherapy in treatment-naïve patients with CLL.2 |
| Key learnings |
| At a median follow-up of 40.8 months, IRC-assessed PFS was longer in both the AV vs FCR/BR (HR, 0.65; 95% CI, 0.49–0.87; p = 0.0038) and AVO vs FCR/BR arms (HR, 0.42; 95% CI, 0.30–0.59; p < 0.0001). |
| PFS was prolonged in the uIgHV subgroup in AV vs FCR/BR (HR, 0.69; 95% CI, 0.48–0.97) and AVO vs FCR/BR arms (HR, 0.35; 95% CI, 0.23–0.53). |
| OS was prolonged in the AV vs FCR/BR arm (HR, 0.33; p < 0.0001), and was prolonged with both AV and AVO vs FCR/BR when censoring for COVID-19 deaths. |
| The EOT uMRD (10−4) rates were higher in the AVO vs AV and FCR/BR arms (67.1% vs 34.4% vs 45.5%) in the ITT population. The incidence of cardiac toxicity remained low in both the AV and AVO arms. |
| Results from the AMPLIFY trial show that a fixed-duration AV and AVO regimen vs chemotherapy resulted in improved PFS in treatment-naïve patients with CLL. |
Abbreviations: AV, acalabrutinib-venetoclax; AVO, acalabrutinib-venetoclax-obinutuzumab; BTKi, Bruton’s tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; EOT, end of treatment; FCR/BR, fludarabine, cyclophosphamide, rituximab/bendamustine, rituximab; HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival; uIgHV, unmutated immunoglobulin heavy-chain variable region; uMRD, undetectable measurable disease.
- Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441-3452. DOI: 10.1200/jco.21.01210
- Brown J. Fixed-duratiocalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial. Oral abstract #1009. American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 10, 2024; San Deigo, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
65 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox